Key result
Overweight and obese patients on DOACs had similar efficacy and safety to normal weight patients, with BMI <25 on rivaroxaban showing higher odds of CRNMB (OR 5.37; 95% CI 1.50-19.32).
Why the study?
There is a paucity of data for DOACs in obese patients, despite their increasingly widespread use.
Are apixaban and rivaroxaban safe and effective in overweight and obese patients with NVAF or VTE compared to normal weight and underweight patients?
Cohort
No
Are apixaban and rivaroxaban safe and effective in overweight and obese patients with NVAF or VTE compared to normal weight and underweight patients?
Odds Ratio: 5.37 (95% CI 1.5–19.32)
Apixaban and rivaroxaban demonstrate similar efficacy and safety profiles in overweight and obese patients compared to normal weight patients for NVAF and VTE management.
No takes yet. Share an insight, caveat, or question.
May support DOAC use in obese NVAF/VTE patients; leaves open need for randomized data in extreme obesity.
Doucette et al. (2020) conducted a cohort in Non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE). Overweight and obesity (BMI ≥25) in patients on DOACs vs. Normal weight and underweight (BMI <25) was evaluated on Major bleeding and clinically relevant nonmajor bleeding (CRNMB) (OR 5.37, 95% CI 1.50-19.32). Overweight and obese patients on DOACs had similar efficacy and safety to normal weight patients, with BMI <25 on rivaroxaban showing higher odds of CRNMB (OR 5.37; 95% CI 1.50-19.32).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: